4-Methylimidazole is used in the manufacture of pharmaceuticals, photographic chemicals, dyes and pigments, cleaning and agricultural chemicals, and rubber. It has been identified as a by-product of fermentation in foods and has been detected in mainstream and sidestream tobacco smoke. 4-Methylimidazole was nominated by the National Cancer Institute for a long-term study because of the high potential for human exposure. Male and female F344/N rats and B6C3F1 mice were exposed to 4-methylimidazole (99.5% pure) in feed for 2 years. Fifteen-day and 14-week toxicity studies of 4-methylimidazole in F344/N rats and B6C3F1 mice are reported in NTP Toxicity Report No. 67. Genetic toxicology studies were conducted in Salmonella typhimurium, rat and mouse bone marrow cells, and mouse peripheral blood.
2-YEAR STUDY IN RATS
Groups of 50 male and 50 female rats were fed diets containing 0, 625, 1,250, or 2,500 ppm 4-methylimidazole (males) or 0, 1,250, 2,500, or 5,000 ppm 4-methylimidazole (females) (equivalent to average daily doses of approximately 30, 55, or 115 mg 4-methylimidazole/kg body weight to males and 60, 120, or 260 mg/kg to females) for 106 weeks. Survival of all exposed groups of male and female rats was similar to that of the control groups. Mean body weights of males in the 1,250 and 2,500 ppm groups and females in the 2,500 and 5,000 ppm groups were less than those of the control groups throughout the study; mean body weights of 1,250 ppm females were less after week 41. Feed consumption by 5,000 ppm females was less than that by the controls. Clonic seizures, excitability, hyperactivity, and impaired gait were observed primarily in 2,500 and 5,000 ppm females.
The incidence of mononuclear cell leukemia in 5,000 ppm females was significantly greater than that in the controls, and the incidence exceeded the historical range in feed study controls. The incidences of hepatic histiocytosis, chronic inflammation, and focal fatty change were generally significantly increased in all exposed groups of male and female rats. The incidences of hepatocellular eosinophilic and mixed cell focus were significantly increased in 2,500 ppm males and 5,000 ppm females.
2-YEAR STUDY IN MICE
Groups of 50 male and 50 female mice were fed diets containing 0, 312, 625, or 1,250 ppm 4-methylimidazole (equivalent to average daily doses of approximately 40, 80, and 170 mg 4-methylimidazole/kg body weight to males and females) for 106 weeks. Survival of all exposed groups of male and female mice was similar to that of the control groups. Mean body weights of males and females in the 1,250 ppm groups were less than those of the control groups after weeks 17 and 12, respectively. Mean body weights of 312 and 625 ppm females were less after weeks 85 and 65, respectively. Feed consumption by exposed groups of male and female mice was generally similar to that by the controls.
The incidences of alveolar/bronchiolar adenoma in all exposed groups of females, alveolar/bronchiolar carcinoma in 1,250 ppm males, and alveolar/bronchiolar adenoma or carcinoma (combined) in 1,250 ppm males and 625 and 1,250 ppm females were significantly greater than those in the control groups. The incidence of alveolar epithelium hyperplasia was significantly increased in 1,250 ppm females.
4-Methylimidazole was not mutagenic in the S. typhimurium mutation assay when tested in strains TA97, TA98, TA100, and TA1535, with and without hamster or rat liver metabolic activation enzymes. No consistent or significant increases in the frequencies of micronucleated erythrocytes were seen in the bone marrow of male rats or mice treated with 4-methylimidazole by intraperitoneal injection, or in peripheral blood samples from male and female mice administered the compound in dosed feed for 14 weeks.
Under the conditions of these 2-year studies, there was no evidence of carcinogenic activity of 4-methylimidazole in male F344/N rats exposed to 625, 1,250, or 2,500 ppm. There was equivocal evidence of carcinogenic activity of 4-methylimidazole in female F344/N rats based on increased incidences of mononuclear cell leukemia. There was clear evidence of carcinogenic activity of 4-methylimidazole in male and female B6C3F1 mice based on increased incidences of alveolar/bronchiolar neoplasms.
Exposure to 4-methylimidazole resulted in nonneoplastic lesions in the liver of male and female rats and the lung of female mice and in clinical findings of neurotoxicity in female rats.
Synonyms: 1H-Imidazole, 4-methyl (9Cl); imidazole, 4-methyl; 4(5)-methylglyoxaline; 4(5),4(5)-methylimidazole; 5-methylimidazole
Trade name: 4-MeI
|0, 625, 1,250, or 2,500 ppm||0, 1,250, 2,500, or 5,000 ppm||0, 312, 625, or 1,250 ppm||0, 312, 625, or 1,250 ppm|
|Body weights||1,250 and 2,500 ppm groups less than the control group||1,250, 2,500, and 5,000 ppm groups less than the control group||1,250 ppm group less than the control group||625 and 1,250 ppm groups less than the control group|
|Survival rates||31/50, 34/50, 33/50, 32/50||43/50, 39/50, 34/50, 35/50||45/50, 44/50, 42/50, 46/50||43/50, 40/50, 43/50, 40/50|
Liver: histiocytosis (38/50, 45/50, 50/50, 50/50); chronic inflammation (18/50, 32/50, 31/50, 36/50); hepatocyte, focal fatty change (21/50, 24/50, 37/50, 33/50); eosinophilic focus (4/50, 3/50, 7/50, 12/50); mixed cell focus (5/50, 7/50, 11/50, 27/50)
Liver: histiocytosis (40/50, 50/50, 48/48, 50/50); chronic inflammation (17/50, 28/50, 34/48, 35/50); hepatocyte, focal fatty change (16/50, 29/50, 29/48, 32/50); eosinophilic focus (1/50, 2/50, 5/48, 11/50); mixed cell focus (10/50, 7/50, 6/48, 18/50)
Lung: alveolar epithelium hyperplasia (3/50, 2/50, 3/50, 11/50)
Lung: alveolar/bronchiolar carcinoma (2/50, 4/50, 4/50, 8/50); alveolar/bronchiolar adenoma or carcinoma (combined) (9/50, 13/50, 16/50, 22/50)
Lung: alveolar/bronchiolar adenoma (0/50, 8/50, 16/50, 8/50); alveolar/bronchiolar carcinoma (3/50, 0/50, 2/50, 7/50); alveolar/bronchiolar adenoma or carcinoma (combined) (3/50, 8/50, 17/50, 14/50)
Monoluclear cell leukemia: (9/50, 7/50, 16/50, 20/50)
|Level of evidence of carcinogenic activity||No evidence||Equivocal evidence||Clear evidence||Clear evidence|
|Bacterial Mutagenicity||Salmonella typhimurium gene mutations:||Negative in strains TA97, TA98, TA100, and TA1535 with and without S9|
|Micronucleated erythrocytes||Rat bone marrow in vivo||Negative when administered by intraperitoneal injection|
|Micronucleated erythrocytes||Mouse marrow in vivo:||Negative when administered by intraperitoneal injection|
|Micronucleated erythrocytes||Mouse peripheral blood in vivo:||Negative in males and females|
Report Date: January 2007